sit tight on your biotron shares, page-25

35,177,627 shares traded thursday , VWAP 17.88c

Whilst its good news Bit is advancing their trials using their compound for anti-viral therapy either alone or in combination for certain HIV/HCV patients there is a small trial just done to cure aids by gene therapy..

http://www.reuters.com/article/2014/03/05/us-hiv-sangamo-idUSBREA242EA20140305

BIT did a trial for HCV alone in 2012 and had good results , i wonder why they didnt pursue a larger 2b trial but instead decided to target those who have HIV and HCV with another small 2a trial. There must be a market for this type of patient where current anti-virals are not effective.

The last time they raised money was in 2011 when almost 80m shares were exercised at 10c. How much they need going forward ???...


228,243,239 Fully paid ordinary shares


2,000,000 30/10/15 $0.22 options.
3,000,000 30/10/15 $0.25 options